SCHEMBL17260201

SCHEMBL17260201

CCCCC[C@@H](C)CCC[C@H](C)CCCC(C)C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.78
ACE2 Q9BYF1 1/20 0.50
BLM P54132 1/20 0.48
OPRM1 P35372 1/20 0.48
PTPN1 P18031 1/20 0.42
MEN1 O00255 1/20 0.42
CYP3A4 P08684 1/20 0.42
ALOX15 P16050 1/20 0.42
KMT2A Q03164 1/20 0.42
CA1 P00915 2/20 0.39
SPHK1 Q9NYA1 1/20 0.39
PRKD3 O94806 1/20 0.39
PRKCG P05129 1/20 0.39
PRKCB P05771 1/20 0.39
PRKCA P17252 1/20 0.39
PRKCH P24723 1/20 0.39
PRKCI P41743 1/20 0.39
PRKCE Q02156 1/20 0.39
PRKCQ Q04759 1/20 0.39
PRKCZ Q05513 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1615056 1.00 LMNA (0.78) LMNAACE2BLMOPRM1PTPN1
SCHEMBL28112288 1.00 LMNA (0.78) LMNAACE2BLMOPRM1PTPN1
SCHEMBL17260206 1.00 LMNA (0.78) LMNAACE2BLMOPRM1PTPN1
SCHEMBL38657276 1.00 LMNA (0.78) LMNAACE2BLMOPRM1PTPN1
SCHEMBL28847035 1.00 LMNA (0.78) LMNAACE2BLMOPRM1PTPN1
SCHEMBL149832 1.00 LMNA (0.78) LMNAACE2BLMOPRM1PTPN1
SCHEMBL23463369 1.00 LMNA (0.78) LMNAACE2BLMOPRM1PTPN1
SCHEMBL10959498 0.97 LMNA (0.74) LMNAACE2BLMOPRM1PTPN1
SCHEMBL23363677 0.97 LMNA (0.74) LMNAACE2BLMOPRM1PTPN1
SCHEMBL23672996 0.97 LMNA (0.74) LMNAACE2BLMOPRM1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452961-B2 (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10-dimetylundec-5-en-2-one or 6,10-dimetylundeca-5,9-dien-2-one DSM IP ASSETS B.V. (NL) 2016-09-27 US disclosed
US-20150329457-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE DSM IP ASSETS B.V. (NL) 2015-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329457-A1 (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE PDE12, CYP2D6, PDE9A LMNA 1447/4885ACE2 284/4885BLM 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.